{"protocolSection": {"identificationModule": {"nctId": "NCT04415658", "orgStudyIdInfo": {"id": "ODRC-002"}, "organization": {"fullName": "Washington University School of Medicine", "class": "OTHER"}, "briefTitle": "Intravenous Thyroxine for Heart-Eligible Organ Donors", "officialTitle": "A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors"}, "statusModule": {"statusVerifiedDate": "2023-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-12-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-11-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-12-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-05-27", "studyFirstSubmitQcDate": "2020-05-29", "studyFirstPostDateStruct": {"date": "2020-06-04", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-10-18", "resultsFirstSubmitQcDate": "2023-12-18", "resultsFirstPostDateStruct": {"date": "2024-01-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-12-18", "lastUpdatePostDateStruct": {"date": "2024-01-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Rajat Dhar", "investigatorTitle": "Professor", "investigatorAffiliation": "Washington University School of Medicine"}, "leadSponsor": {"name": "Washington University School of Medicine", "class": "OTHER"}, "collaborators": [{"name": "Mid-America Transplant", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo", "detailedDescription": "Background: Brain death frequently induces hemodynamic instability and cardiac stunning. Impairments in cardiac performance are major contributors to hearts from otherwise eligible organ donors not being transplanted. Deficiencies in pituitary hormones (including thyroid stimulating hormone) may contribute to hemodynamic instability and replacement of thyroid hormone has been proposed as a means of improving stability and increasing hearts available for transplantation. Intravenous thyroxine is commonly used in donor management. However, small controlled trials have not been able to demonstrate efficacy.\n\nMethods: This multicenter study will involve organ procurement organizations (OPOs) across the country. A total of 800 heart-eligible brain dead organ donors who require vasopressor support will be randomly assigned to intravenous thyroxine for at least 12-hours or saline placebo. The primary study hypothesis is that thyroxine treatment results in more hearts transplanted. Additional outcome measures are time to achieve hemodynamic stability (weaning off vasopressors) and improvement in cardiac ejection fraction on echocardiography.\n\nDiscussion: This will be the largest randomized controlled study to evaluate the efficacy of thyroid hormone treatment for organ donor management. By collaborating across multiple OPOs, it will be able to enroll an adequate number of donors and be powered to definitively answer the critical question of whether treatment increases hearts transplanted and/or provides other hemodynamic benefits."}, "conditionsModule": {"conditions": ["Brain Death", "Heart Failure"], "keywords": ["Organ donor"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 838, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Thyroxine", "type": "EXPERIMENTAL", "description": "Intravenous thyroxine infusion", "interventionNames": ["Drug: Thyroxine"]}, {"label": "Saline Placebo", "type": "PLACEBO_COMPARATOR", "description": "Intravenous saline infusion", "interventionNames": ["Drug: Saline"]}], "interventions": [{"type": "DRUG", "name": "Thyroxine", "description": "Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours.", "armGroupLabels": ["Thyroxine"]}, {"type": "DRUG", "name": "Saline", "description": "The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.", "armGroupLabels": ["Saline Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Heart Transplanted", "description": "Whether heart is transplanted into living recipient", "timeFrame": "One week"}, {"measure": "Graft Function", "description": "30-day graft survival of hearts transplanted from study donors, obtained from SRTR recipient registry", "timeFrame": "30 days"}], "secondaryOutcomes": [{"measure": "Time Till Off Vasopressors", "description": "Time in hours from randomization to when weaned off vasopressors (except vasopressin)", "timeFrame": "72 hours"}, {"measure": "Weaned Off Vasopressors", "description": "Weaned off vasopressors within twelve hours", "timeFrame": "12 hours"}, {"measure": "Time to Order Echo", "description": "Time till hemodynamic stability permits ordering initial echocardiogram", "timeFrame": "72 hours"}, {"measure": "Ejection Fraction", "description": "Left ventricular ejection fraction measured on first echocardiography", "timeFrame": "72 hours"}, {"measure": "Lungs Transplanted", "description": "Whether the lungs were transplanted into a living recipient", "timeFrame": "72 hours"}], "otherOutcomes": [{"measure": "Total Organs Transplanted", "description": "Total number of organs transplanted (incl. lungs, liver, kidneys, heart, pancreas)", "timeFrame": "One week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Declared dead by neurologic criteria (brain dead)\n* Authorization for organ donation and research\n* On one or more vasopressors and/or inotropes\n\nExclusion Criteria:\n\n* Brain death declared more than 24 hours prior\n* Only vasopressor is vasopressin\n* Weight \\< 45 kg (100 lbs)\n* Known coronary artery disease or history of myocardial infarction\n* Known valvular heart disease\n* Prior sternotomy or cardiac surgery\n* Donor at VA hospital\n* Received intravenous or oral thyroxine within past month\n* Known HIV+ status\n* Other reason donor is unable to receive study drug (determined by on-site personnel)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "14 Years", "maximumAge": "55 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rajat Dhar, MD", "affiliation": "Washington University School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Donor Network of Arizona", "city": "Phoenix", "state": "Arizona", "zip": "85013", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Lifesharing", "city": "San Diego", "state": "California", "zip": "92108", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Donor Alliance", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "OurLegacy", "city": "Maitland", "state": "Florida", "zip": "32751", "country": "United States", "geoPoint": {"lat": 28.62778, "lon": -81.36312}}, {"facility": "Iowa Donor Network", "city": "North Liberty", "state": "Iowa", "zip": "52317", "country": "United States", "geoPoint": {"lat": 41.74918, "lon": -91.59795}}, {"facility": "Midwest Transplant Network", "city": "Westwood", "state": "Kansas", "zip": "66205", "country": "United States", "geoPoint": {"lat": 39.04056, "lon": -94.6169}}, {"facility": "Louisiana Organ Procurement Agency", "city": "Covington", "state": "Louisiana", "zip": "70433", "country": "United States", "geoPoint": {"lat": 30.47549, "lon": -90.10042}}, {"facility": "Mid-America Transplant Services", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Lifebanc", "city": "Cleveland", "state": "Ohio", "zip": "44128", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "LifeShare of Oklahoma", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73132", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Southwest Transplant Alliance", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Texas Organ Sharing Alliance", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "DonorConnect", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "LifeCenter Northwest", "city": "Bellevue", "state": "Washington", "zip": "98006", "country": "United States", "geoPoint": {"lat": 47.61038, "lon": -122.20068}}]}, "referencesModule": {"references": [{"pmid": "30689222", "type": "BACKGROUND", "citation": "Dhar R, Stahlschmidt E, Yan Y, Marklin G. A randomized trial comparing triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable brain-dead organ donors. Clin Transplant. 2019 Mar;33(3):e13486. doi: 10.1111/ctr.13486. Epub 2019 Feb 12."}, {"pmid": "31802716", "type": "BACKGROUND", "citation": "Dhar R, Stahlschmidt E, Marklin G. A Randomized Trial of Intravenous Thyroxine for Brain-Dead Organ Donors With Impaired Cardiac Function. Prog Transplant. 2020 Mar;30(1):48-55. doi: 10.1177/1526924819893295. Epub 2019 Dec 5."}, {"pmid": "38048188", "type": "BACKGROUND", "citation": "Dhar R, Marklin GF, Klinkenberg WD, Wang J, Goss CW, Lele AV, Kensinger CD, Lange PA, Lebovitz DJ. Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors. N Engl J Med. 2023 Nov 30;389(22):2029-2038. doi: 10.1056/NEJMoa2305969."}, {"pmid": "34838132", "type": "DERIVED", "citation": "Dhar R, Klinkenberg D, Marklin G. A multicenter randomized placebo-controlled trial of intravenous thyroxine for heart-eligible brain-dead organ donors. Trials. 2021 Nov 27;22(1):852. doi: 10.1186/s13063-021-05797-2."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Researchers within the study consortium only"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "FG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "periods": [{"title": "Initial Study Period (12 Hours)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "419"}, {"groupId": "FG001", "numSubjects": "419"}]}, {"type": "Started Assigned Infusion", "achievements": [{"groupId": "FG000", "numSubjects": "411"}, {"groupId": "FG001", "numSubjects": "384"}]}, {"type": "Per-Protocol", "comment": "Received assigned intervention for at least six hours", "achievements": [{"groupId": "FG000", "numSubjects": "351"}, {"groupId": "FG001", "numSubjects": "374"}]}, {"type": "Cross-over", "comment": "Crossed-over to other intervention within 12 hours", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Stopped Infusion Early", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "COMPLETED", "comment": "Refers to completing donor care, with organ allocation outcomes available", "achievements": [{"groupId": "FG000", "numSubjects": "333"}, {"groupId": "FG001", "numSubjects": "416"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "3"}]}]}, {"title": "Open-Label (T4 Beyond 12 Hours)", "milestones": [{"type": "STARTED", "comment": "Total number of donors eligible to receive open-label", "achievements": [{"groupId": "FG000", "numSubjects": "333"}, {"groupId": "FG001", "numSubjects": "416"}]}, {"type": "COMPLETED", "comment": "number who received thyroxine infusion beyond initial 12-hour study period", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "124"}, {"groupId": "FG001", "numSubjects": "366"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "BG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "36", "spread": "11"}, {"groupId": "BG001", "value": "36", "spread": "10"}, {"groupId": "BG002", "value": "36", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "missing data for 16 in T4 and 19 in NS group", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "400"}, {"groupId": "BG002", "value": "803"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "280"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "276"}, {"groupId": "BG001", "value": "247"}, {"groupId": "BG002", "value": "523"}]}]}]}, {"title": "Race/Ethnicity, Customized", "populationDescription": "Missing data on 16 in T4 and 22 in NS group", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White, non-Hispanic", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "252"}, {"groupId": "BG001", "value": "278"}, {"groupId": "BG002", "value": "530"}]}]}, {"title": "Black", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "75"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "124"}]}]}, {"title": "Hispanic", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "123"}]}]}, {"title": "Asian, Pacific-Islander, other", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}]}]}, {"title": "Blood Group", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "O", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "224"}, {"groupId": "BG001", "value": "214"}, {"groupId": "BG002", "value": "438"}]}]}, {"title": "A", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "282"}]}]}, {"title": "B", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "99"}]}]}, {"title": "AB", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "419"}, {"groupId": "BG002", "value": "838"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Cause of Death", "populationDescription": "missing demographic data for 16 in T4 and 22 in NS group", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Anoxia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "195"}, {"groupId": "BG002", "value": "357"}]}]}, {"title": "Stroke / Cerebrovascular", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "166"}]}]}, {"title": "Trauma", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "260"}]}]}, {"title": "Other", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "403"}, {"groupId": "BG001", "value": "397"}, {"groupId": "BG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Heart Transplanted", "description": "Whether heart is transplanted into living recipient", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "One week", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "419"}, {"groupId": "OG001", "value": "419"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "223"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "80% power to detect a 10% increase in hearts transplanted", "nonInferiorityType": "SUPERIORITY", "pValue": "0.57", "statisticalMethod": "Chi-squared, Corrected", "paramType": "Risk Ratio (RR)", "paramValue": "1.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "1.07"}]}, {"type": "PRIMARY", "title": "Graft Function", "description": "30-day graft survival of hearts transplanted from study donors, obtained from SRTR recipient registry", "populationDescription": "Only out of those hearts that were transplanted (not all study participants)", "reportingStatus": "POSTED", "paramType": "COUNT_OF_UNITS", "unitOfMeasure": "hearts", "timeFrame": "30 days", "typeUnitsAnalyzed": "hearts", "denomUnitsSelected": "hearts", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "223"}]}, {"units": "hearts", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "223"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "213"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Non-inferiority analysis for thyroxine vs saline", "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Six percent margin, assuming 96% graft survival in control group", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Mean Difference (Final Values)", "paramValue": "1.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "6.0"}]}, {"type": "SECONDARY", "title": "Time Till Off Vasopressors", "description": "Time in hours from randomization to when weaned off vasopressors (except vasopressin)", "populationDescription": "out of those who began study infusion on vasopressors", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "404"}, {"groupId": "OG001", "value": "385"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22", "lowerLimit": "19", "upperLimit": "31"}, {"groupId": "OG001", "value": "25", "lowerLimit": "19", "upperLimit": "38"}]}]}]}, {"type": "SECONDARY", "title": "Weaned Off Vasopressors", "description": "Weaned off vasopressors within twelve hours", "populationDescription": "out of those who began the study infusion still on vasopressors (i.e. some had been weaned off prior to infusion)", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "404"}, {"groupId": "OG001", "value": "388"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "152"}]}]}]}, {"type": "SECONDARY", "title": "Time to Order Echo", "description": "Time till hemodynamic stability permits ordering initial echocardiogram", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "409"}, {"groupId": "OG001", "value": "385"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12", "lowerLimit": "11", "upperLimit": "13"}, {"groupId": "OG001", "value": "13", "lowerLimit": "12", "upperLimit": "14"}]}]}]}, {"type": "SECONDARY", "title": "Ejection Fraction", "description": "Left ventricular ejection fraction measured on first echocardiography", "populationDescription": "only those who had echocardiography performed after study start", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of ejection fraction", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "350"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "59", "spread": "11"}, {"groupId": "OG001", "value": "58", "spread": "12"}]}]}]}, {"type": "SECONDARY", "title": "Lungs Transplanted", "description": "Whether the lungs were transplanted into a living recipient", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "419"}, {"groupId": "OG001", "value": "419"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "149"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Total Organs Transplanted", "description": "Total number of organs transplanted (incl. lungs, liver, kidneys, heart, pancreas)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "organs", "timeFrame": "One week", "groups": [{"id": "OG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours."}, {"id": "OG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "419"}, {"groupId": "OG001", "value": "419"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4", "lowerLimit": "3", "upperLimit": "5"}, {"groupId": "OG001", "value": "4", "lowerLimit": "3", "upperLimit": "5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "1 week", "description": "Serious adverse event defined as donor instability resulting in cardiac arrest or premature donor loss.\n\nAdverse events were collected for each arm combining all study periods, i.e. from study onset through end of donor management (organ recovery). These were not collected for each period (i.e. first 12 hours versus open-label period) separately.", "eventGroups": [{"id": "EG000", "title": "Thyroxine", "description": "Intravenous thyroxine infusion\n\nThyroxine: Infusion prepared by mixing 500 \u03bcg of drug in 500-ml of normal saline (i.e. concentration of 1 \u03bcg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 \u03bcg/hour (30 ml/hour) for twelve hours.\n\nDonors were followed till organ recovery or end of management.", "deathsNumAffected": 419, "deathsNumAtRisk": 419, "seriousNumAffected": 2, "seriousNumAtRisk": 419, "otherNumAffected": 51, "otherNumAtRisk": 419}, {"id": "EG001", "title": "Saline Placebo", "description": "Intravenous saline infusion\n\nSaline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.\n\nDonors were followed till organ recovery or end of management.", "deathsNumAffected": 419, "deathsNumAtRisk": 419, "seriousNumAffected": 3, "seriousNumAtRisk": 419, "otherNumAffected": 16, "otherNumAtRisk": 419}], "seriousEvents": [{"term": "Cardiac arrest / donor loss", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Hemodynamic instability resulting in cardiac arrest and/or donor loss", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 419}]}], "otherEvents": [{"term": "Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 16, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 419}]}, {"term": "Hypertension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 26, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 419}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 419}]}, {"term": "Ventricular ectopy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 419}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "not including unstable/leading to arrest", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 419}]}, {"term": "Misc/Other", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "includes rash, electrolyte disturbance, respiratory distress, pulmonary edema, hypotension", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 419}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 419}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Not blinded, open-label use of levothyroxine permitted in control group after 12 hours (only 50 donors in that group received open-label, plus three who crossed-over to levothyroxine immediately after randomization)"}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Rajat Dhar", "organization": "Washington University in St. Louis School of Medicine", "email": "dharr@wustl.edu", "phone": "3143622999"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol: Appendix (Data Forms)", "date": "2020-12-01", "uploadDate": "2020-12-07T15:48", "filename": "Prot_003.pdf", "size": 1352729}, {"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan: Study Protocol and SAP", "date": "2021-11-01", "uploadDate": "2021-11-22T12:08", "filename": "Prot_SAP_005.pdf", "size": 865886}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-11-09", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001926", "term": "Brain Death"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000003128", "term": "Coma"}, {"id": "D000014474", "term": "Unconsciousness"}, {"id": "D000003244", "term": "Consciousness Disorders"}, {"id": "D000019954", "term": "Neurobehavioral Manifestations"}, {"id": "D000009461", "term": "Neurologic Manifestations"}, {"id": "D000003643", "term": "Death"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "relevance": "LOW"}, {"id": "M6845", "name": "Death", "relevance": "LOW"}, {"id": "M5203", "name": "Brain Death", "asFound": "Brain Death", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M6356", "name": "Coma", "relevance": "LOW"}, {"id": "M17224", "name": "Unconsciousness", "relevance": "LOW"}, {"id": "M6468", "name": "Consciousness Disorders", "relevance": "LOW"}, {"id": "M21826", "name": "Neurobehavioral Manifestations", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}}, "hasResults": true}